In February 2023, a devastating earthquake hit Turkey. Fosun Foundation joined hands with the Group's German member company Tom Tailor and Fosun Trade to make an emergency donation, and became the first charitable force in Shanghai to respond to the disaster. Artesun® (artesunate for injection), an innovative drug with proprietary intellectual property rights owned by Fosun Pharma, has treated more than 56 million severe malaria patients worldwide and covered 175 million children in African countries with high malaria prevalence. In June 2023, Argesun®, the second-generation artesunate for injection independently developed by Fosun Pharma, became the first artesunate injectable with the WHO prequalification, which will further enhance the accessibility of innovative antimalarial drugs and save more lives.